Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 07 Apr 2026
ICER releases draft evidence report on vaccines for Covid-19
7 April 2026 - Public comment period now open until 4 May 2026; requests to make oral comment during public ...
Posted by Michael Wonder on 07 Apr 2026
Update from the PBAC (March 2026)
7 April 2026 - The latest meeting of the PBAC was held 11 – 13 March 2026. ...
Posted by Michael Wonder on 07 Apr 2026
PHARMAC widens access to two melanoma medicines
7 April 2026 - PHARMAC will widen access to two melanoma medicines, giving New Zealanders another funded immunotherapy option and ...
Posted by Michael Wonder on 06 Apr 2026
MSAC publishes agenda for July 2026 MSAC meeting
7 April 2026 - The MSAC Secretariat has published a list of applications scheduled to be considered by the MSAC on ...
Posted by Michael Wonder on 06 Apr 2026
Padcev, Tavneos clear key step toward reimbursement in Korea
3 April 2026 - Astellas Pharma Korea’s Padcev (enfortumab vedotin) for urothelial carcinoma and Meditip’s Tavneos (avacopan) for rare vasculitides ...
Posted by Michael Wonder on 05 Apr 2026
‘Life-changing’ eczema drug for children caught in $16,000/year PBS limbo
5 April 2026 - A prescription medication for a debilitating skin condition that is listed on the PBS for adults ...
Posted by Michael Wonder on 04 Apr 2026
US hikes tariffs on Korean patented drugs, spares biosimilars for year
3 April 2026 - Korean drug makers eye US manufacturing labels and limited exemptions as Washington targets patented meds with new ...
Posted by Michael Wonder on 04 Apr 2026
European Commission approves Keytruda (pembrolizumab) plus paclitaxel ± bevacizumab for the treatment of adults with PD-L1 (CPS ≥1) platinum-resistant recurrent ovarian carcinoma who have received one or two prior systemic treatment regimens
2 April 2026 - Merck announced that Keytruda (pembrolizumab), in combination with paclitaxel, with or without bevacizumab, is approved in the ...
Posted by Michael Wonder on 03 Apr 2026
Trump announces 100% tariffs on brand name drugs, with plenty of carveouts
2 April 2026 - The taxes won’t apply to many large drugmakers or to some of the US’ biggest trading ...
Posted by Michael Wonder on 03 Apr 2026
Butler ‘confident’ of CSL exemption as Australian drugs incur 100pc tariff
3 April 2026 - The Health Minister is hopeful the country’s largest biotech firm CSL will be exempt after Australia was ...
Posted by Michael Wonder on 03 Apr 2026
Sevabertinib approved to treat adults with HER2 positive lung cancer that has spread or cannot be removed by surgery
2 April 2026 - The MHRA has approved sevabertinib (Hyrnuo) to treat adults with advanced non-small cell lung cancer with ...
Posted by Michael Wonder on 03 Apr 2026
NHS patients and British businesses to benefit from historic changes to medicines access following pharmaceutical partnership with US
2 April 2026 - New partnership accelerates NHS patients' access to new medicines and will see UK benefit from greater life ...
Posted by Michael Wonder on 03 Apr 2026
Trump slaps 100pc tariffs on Australian drugs – with exceptions
3 April 2026 - Australian drug makers that do not build new factories in America and dramatically cut their prices ...
Posted by Michael Wonder on 03 Apr 2026
Changes to NICE’s cost effectiveness thresholds take effect
2 April 2026 - NICE has implemented new measures to evaluate the cost effectiveness of medicines, following a policy change that ...
Posted by Michael Wonder on 03 Apr 2026
MHRA-NICE pathway opens for business – everything you need to know to get started
1 April 2026 - Today marks a significant milestone for patients, the NHS and the pharmaceutical industry. From 1 April 2026, ...